Sees FY25 net product sales $185M-$192M; and contract revenues from collaborations $15M-$18M. The company added, “The revenue ranges above exclude approximately $40.0 million in non-cash revenue that Rigel expects to recognize in the Q2 related to the release of the remaining cost share liability from Rigel’s collaboration with Lilly for the development and commercialization of ocadusertib. The company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL: